Regeneron Reports registry Data for Nivolumab in Follicular lymphoma

Regeneron today announced registry results for nivolumab in patients with follicular lymphoma. The study demonstrated that nivolumab demonstrates safety and tolerability compared to standard of care or placebo. These results provide important insights into the treatment of follicular lymphoma and support the continued development of nivolumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.